Ebola Outbreak Update: Bundibugyo Strain Surpasses 600 Cases Across DRC & Uganda

The ongoing Ebola outbreak in the Democratic Republic of the Congo (DRC) and Uganda has now exceeded 600 confirmed cases and 117 deaths, only weeks after the WHO declared it a Public Health Emergency of International Concern (PHEIC). This event marks one of the most significant re-emergences of the Bundibugyo strain, a rare variant for which no vaccines or therapeutics are approved. Why This Outbreak Is Different • Bundibugyo orthoebolavirus is making only its third major appearance in recorded history. • With no licensed countermeasures, clinical teams rely solely on supportive care. • Global partners—including CEPI and Moderna—are accelerating Phase 1 vaccine development, but timelines remain uncertain. Current Epidemiology • DRC: 598 cases, 115 deaths, concentrated in Ituri Province with spread into North & South Kivu. • Uganda: 19 cases, 2 deaths, primarily in Kampala and Wakiso. Operational Realities on the Ground • Transmission zones overlap with active conflict, limiting access and fueling mistrust. • Over 2 million displaced people reside in high-risk regions. • Health systems face shortages in PPE, water, transport, and staffing, with 34 infected healthcare workers to date. Global Travel & Policy Impact • The U.S. has implemented enhanced screening and temporary travel restrictions for travelers from affected countries. • Calls for broader international restrictions continue, though WHO warns that blanket bans may disrupt critical supply chains. How GRN IVD Consulting Supports Diagnostics Leaders Outbreaks like this reshape the landscape for infectious disease testing, market demand, and technology readiness.

At GRN IVD Consulting, we help diagnostics manufacturers, investors, and health system partners navigate these shifts with: • Real-time outbreak intelligence • Comparative assay and platform analysis • Market sizing & adoption modeling • Clinical algorithm mapping for high-consequence pathogens • Executive-grade insights for commercial and R&D strategy As the situation evolves, clear, data-driven decision support becomes essential. GRN IVD Consulting ensures your strategy stays aligned with clinical realities and global demand signals.